Cargando…

Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)

Adoptive cell therapy (ACT) for the treatment of solid malignancies has not met yet the success of hematological malignancies. This is due to additional roadblocks peculiar to its deployment for the former application. While T-cell fitness stands as a prerequisite for all purposes of ACT, selection...

Descripción completa

Detalles Bibliográficos
Autores principales: Markovska, Martina, Marincola, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798779/
https://www.ncbi.nlm.nih.gov/pubmed/33419860
http://dx.doi.org/10.1136/jitc-2020-002216
_version_ 1783635082902241280
author Markovska, Martina
Marincola, Francesco
author_facet Markovska, Martina
Marincola, Francesco
author_sort Markovska, Martina
collection PubMed
description Adoptive cell therapy (ACT) for the treatment of solid malignancies has not met yet the success of hematological malignancies. This is due to additional roadblocks peculiar to its deployment for the former application. While T-cell fitness stands as a prerequisite for all purposes of ACT, selection of optimal tumor-specific antigens, efficient trafficking to neoplastic tissues, and overcoming immune exclusion and/or suppression are challenges pertaining predominantly to solid malignancies. To gain insights about the current interest on the subject in both academia and industry, we surveyed a snapshot of topical activities and checked the pulse of the field by reviewing content extracted from 94 abstracts submitted, under the subject “cellular therapies”, to the 35th Anniversary Annual Meeting of the Society for the Immunotherapy of Cancer.
format Online
Article
Text
id pubmed-7798779
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77987792021-01-21 Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020) Markovska, Martina Marincola, Francesco J Immunother Cancer Commentary Adoptive cell therapy (ACT) for the treatment of solid malignancies has not met yet the success of hematological malignancies. This is due to additional roadblocks peculiar to its deployment for the former application. While T-cell fitness stands as a prerequisite for all purposes of ACT, selection of optimal tumor-specific antigens, efficient trafficking to neoplastic tissues, and overcoming immune exclusion and/or suppression are challenges pertaining predominantly to solid malignancies. To gain insights about the current interest on the subject in both academia and industry, we surveyed a snapshot of topical activities and checked the pulse of the field by reviewing content extracted from 94 abstracts submitted, under the subject “cellular therapies”, to the 35th Anniversary Annual Meeting of the Society for the Immunotherapy of Cancer. BMJ Publishing Group 2021-01-08 /pmc/articles/PMC7798779/ /pubmed/33419860 http://dx.doi.org/10.1136/jitc-2020-002216 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Commentary
Markovska, Martina
Marincola, Francesco
Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)
title Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)
title_full Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)
title_fullStr Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)
title_full_unstemmed Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)
title_short Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)
title_sort letter to the editor: checking the pulse of adoptive cell therapy for solid tumors. thoughts from the abstracts submitted to the 35th annual meeting of the society for the immunotherapy of cancer (sitc 2020)
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798779/
https://www.ncbi.nlm.nih.gov/pubmed/33419860
http://dx.doi.org/10.1136/jitc-2020-002216
work_keys_str_mv AT markovskamartina lettertotheeditorcheckingthepulseofadoptivecelltherapyforsolidtumorsthoughtsfromtheabstractssubmittedtothe35thannualmeetingofthesocietyfortheimmunotherapyofcancersitc2020
AT marincolafrancesco lettertotheeditorcheckingthepulseofadoptivecelltherapyforsolidtumorsthoughtsfromtheabstractssubmittedtothe35thannualmeetingofthesocietyfortheimmunotherapyofcancersitc2020